Sep 27, 2021 - Health

The new booster dilemma

Caitlin Owens

Illustration of a syringe bent into the shape of a number three — Illustration: Annelise Capossela/Axios

A rush of patients — and their questions — followed last week's news that the CDC and FDA would greenlight Pfizer-BioNTech COVID boosters, the Washington Post reported.

Driving the news: The recommendation that those older than 65, the immunocompromised and those in high-risk jobs includes a lot of people — but it left out most who received the Moderna shot and all who received Johnson & Johnson.

The wait for boosters news is making some non-Pfizer vaccine recipients a bit salty.

What they're saying: "After months of confusion, there remains more or less radio silence on the J&J question," wrote Benjamin Hart of the Intelligencer.

"Never mind that a growing body of evidence shows that we could use another dose more than the Pfizer Pfanatics or Moderna Mafia," he said.

What to watch: J&J said in a press release last week that a global study showed boosters helped increase the protection of its COVID shot. Moderna similarly has said data supports boosters and has submitted for FDA approval.

Fauci has said both are a few weeks away from FDA review.

Add Axios on Google

The new booster dilemma

What to read next